Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.54 +0.21 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years. 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Looking Into Teva Pharmaceutical Indus's Recent Short Interest
 
Via Benzinga
Teva Releases Q2 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
How Do Investors Really Feel About Teva Pharmaceutical Indus?
 
Via Benzinga
Where Teva Pharmaceutical Indus Stands With Analysts
 
Via Benzinga
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
 
Via Benzinga
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
Via The Motley Fool
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base. 
Via Benzinga
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.